Evidence map›Paper›PMID 33119552›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2020

Centrosome Protein 78 Is Overexpressed in Muscle-Invasive Bladder Cancer and Is Associated with Tumor Molecular Subtypes and Mutation Signatures.

Xiaoli Huang, Yang Yan, Rong Wei, Hu Liu, Xingchen Zhu, Dexi Bi, Qing Wei, Xudong Yao

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xiaoli HuangDepartment of Pathology, Shanghai Clinical College, Anhui Medical University, Hefei, Anhui, China (mainland).
Yang YanDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China (mainland).
Rong WeiDepartment of Pathology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China (mainland).
Hu LiuDepartment of Pathology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China (mainland).
Xingchen ZhuDepartment of Pathology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China (mainland).
Dexi BiDepartment of Pathology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China (mainland).
Qing WeiDepartment of Pathology, Shanghai Clinical College, Anhui Medical University, Hefei, Anhui, China (mainland).
Xudong YaoDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China (mainland).
Shanghai Tenth People's Hospital · CNAnhui Medical University · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Centrosome aberrations have long been linked to tumorigenesis. Centrosome protein 78 (CEP78) is a centrosome component that is required to regulate the cell cycle, but its role in bladder cancer has not been elucidated. MATERIAL AND METHODS Real-time quantitative polymerase chain reaction and immunohistochemistry were used to examine the expression of CEP78 in bladder cancer tissues and adjacent non-cancer tissues. RESULTS Analysis of the RNA-Seq data from the TCGA (The Cancer Genome Atlas) MIBC cohort (n=408) revealed that CEP78 was overexpressed in tumor tissues, which was confirmed with fresh-frozen and formalin-fixed paraffin-embedded specimens collected from 28 and 33 MIBC patients, respectively, in the present study. The clinicopathological relevance of CEP78 was further investigated. High CEP78 expression was found to be correlated with non-papillary histological type, luminal, basal-squamous and neuronal molecular subtypes, TP53 mutation, RB1 mutation, wild-type FGFR3, PPARG fusion and amplification, high total number of single-nucleotide variants, and high neoantigen load, but it was not associated with tumor stages or overall survival. CONCLUSIONS The results of this study suggest that CEP78 plays in a role in promoting the development of MIBC and could be a novel diagnostic and therapeutic target.

Indexed as

AgedBiomarkers, TumorCarcinogenesisCell Cycle ProteinsCohort StudiesFemaleHumansMaleMiddle AgedMusclesUrinary Bladder NeoplasmsBiomarkers, TumorCell Cycle ProteinsCEP78 protein, human

Identifiers

PMID33119552
PMCPMC7607667
OpenAlexW3084821084

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.